A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and Older
A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and Older
The study will enroll up to 27,200 participants in order to demonstrate the efficacy of the active Ad26.RSV.preF-based study vaccine in the prevention of Reverse Transcription Polymerase Chain Reaction (RT-PCR) confirmed Respiratory Syncytial Virus (RSV)-mediated Lower Respiratory Tract Disease (LRTD) when compared to placebo in adults aged 60 years and above.
Inclusion Criteria:
Exclusion Criteria:
Fort Myers, Florida 33912, United States
New Orleans, Louisiana 70119, United States
São José do Rio Preto, 15090 000, Brazil
Quilota, 2260734, Chile
Main Road Stoke, 7011, New Zealand
Western Cape, 7626, South Africa
Taoyuan County, 33305, Taiwan
Muang, 50200, Thailand
Pathumwan, 10330, Thailand